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Research
Bisphenol A (BPA), a synthetic estrogen, and 
alkylphenols (APs) are widely used indus-
trial chemicals that have received tremendous 
media and research attention in recent years 
because of their estrogenic endocrine-disrupt-
ing properties (Turner and Sharpe 1997). 
Humans are exposed to these environmen-
tal phenolic compounds through foods and 
beverages as well as air, drinking water, dust, 
soil, and personal care products (Vandenberg 
et al. 2007). BPA and APs [including 4-tert-
octylphenol (tOP), benzophenone-3 (BP-3), 
and the chlorophenol triclosan] may rapidly 
be cleared by the kidneys and excreted in urine 
(Dekant and Völkel 2008; Kadry et al. 1995; 
Kawaguchi et al. 2004; Sandborgh-Englund 
et al. 2006). By measuring urinary levels of 
these compounds, Calafat et al. (2005, 2008a, 
2008b, 2008c) have shown that nearly all 
(BPA and BP-3) and three-quarters (triclosan) 
of free-living humans had measurable quanti-
ties of these chemicals in their urine.
In a recent cross-sectional study, Stahlhut 
et al. (2009) compared subjects who reported 
various lengths of fasting time and found that 
reported fasting time did not matter as much 
as expected when comparing longer fasting 
with shorter fasting subjects. There is a pos-
sibility that BPA may accumulate in body tis-
sues. Because BPA is cleared by the kidneys, 
the pharmacokinetics of environmental phe-
nols could be very different in populations 
with impaired renal function. In the present 
study, we evaluated the hypothesis that urinary 
excretion of BPA and APs may be reduced 
among people with insufficient renal function, 
as measured by estimated glomerular filtra-
tion rate (eGFR) using newly available data 
from the 2003–2006 National Health and 
Nutrition Examination Survey (NHANES).
Materials and Methods
Study population. We used data from the 
2003–2006 NHANES for this analysis. 
NHANES, conducted by the Centers for 
Disease Control and Prevention (CDC), 
National Center for Health Statistics (NCHS), 
investigates a nationally representative sample 
using a multistage, stratified, clustered sam-
pling strategy among the civilian, noninstitu-
tionalized U.S. population. The 2003–2006 
NHANES was reviewed and approved by the 
NCHS Institutional Review Board. Details on 
the methods used in the NHANES surveys are 
described elsewhere (CDC 2011).
In the 2003–2006 NHANES, a one-
third subsample of participants ≥ 6 years of 
age (2,638 from the 2003–2004 NHANES 
and 2,612 from the 2005–2006 NHANES) 
was randomly selected for the assay of uri-
nary excretion rate of BPA and APs; 185 par-
ticipants with missing BPA and AP data and 
953 participants with missing serum creatinine 
(Scr) or urinary creatinine (Scr was used to 
estimate kidney function) data were excluded. 
It is possible that people with known renal dis-
eases may change their usual diet, which may 
in turn lead to alterations in levels of BPA and 
APs. Therefore, we excluded from our analysis 
61 participants who reported that they had 
weak or failing kidneys and those who had 
received dialysis in the previous 12 months. 
Because history of renal diseases was collected 
only from those ≥ 20 years of age, we excluded 
1,302 participants who were < 20 years of age. 
Also excluded were 176 pregnant or lactat-
ing females. As a result, 2,573 adults were 
included in the final analysis.
Assessment of urinary BPA and APs con-
centrations. One spot urine sample was col-
lected from participants in the 2003–2006 
NHANES. Urinary BPA and APs were meas-
ured at the Division of Environmental Health 
Laboratory Sciences, National Center for 
Environmental Health, via online solid-phase 
extraction coupled with high-performance liq-
uid chromatography/isotope-dilution and tan-
dem mass spectrometry (CDC 2007, 2009). 
A comprehensive quality control mechanism 
(CDC 2007, 2009), including reagent blanks, 
was used to prevent contamination during 
urine specimen handling, storage, shipping, 
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Ba c k g r o u n d: Urinary excretion of bisphenol A (BPA) and alkylphenols (APs) was used as a 
  biomarker in most previous studies, but no study has investigated whether urinary excretion of 
these environmental phenols differed by renal function.
oB j e c t i v e: We estimated the association between renal function and urinary excretion of BPA 
and APs.
Me t h o d s : Analyses were conducted using data from the National Health and Nutrition 
Examination Survey (NHANES) 2003–2006. Renal function was measured as estimated glomeru-
lar filtration rate (eGFR) calculated by the Modification of Diet in Renal Disease (MDRD) Study 
equation and by the newly developed Chronic Kidney Disease Epidemiology Collaboration (CKD-
EPI) equation. Regression models were used to calculate geometric means of urinary BPA and APs 
excretion by eGFR category (≥ 90, 60–90, < 60 mL/min/m2) after adjusting for potential confound-
ing factors.
re s u l t s: When we used the MDRD Study equation, participants without known renal disease 
(n = 2,573), 58.2% (n = 1,499) had mildly decreased renal function or undiagnosed chronic kidney 
disease. The adjusted geometric means for urinary BPA excretion decreased with decreasing levels 
of eGFR (p for trend = 0.04). The associations appeared primarily in females (p for trend = 0.03). 
Urinary triclosan excretion decreased with decreasing levels of eGFR (p for trend < 0.01) for both 
males and females, and the association primarily appeared in participants < 65 years of age. The 
association between BPA and eGFR was nonsignificant when we used the CKD-EPI equation.
co n c l u s i o n s : Urinary excretion of triclosan, and possibly BPA, decreased with decreasing renal 
function. The associations might differ by age or sex. Further studies are necessary to replicate our 
results and understand the mechanism.
key w o r d s : APs, BPA, NHANES, renal function, urinary excretion. Environ Health Perspect 
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and analysis. For concentrations below the 
limit of detection (LOD), values equal to the 
LOD divided by the square root of 2 were 
used (Calafat et al. 2008a, 2008b, 2008c). 
According to the Fourth National Report on 
Human Exposure to Environmental Chemicals, 
the 2003–2004 data for tOP have been 
removed (CDC 2010). Thus, we did not 
include tOP in the present study.
Measures of renal function. Of the 
2003–2006 NHANES participants, > 92% 
donated a blood sample. Scr was measured 
using a kinetic rate Jaffe method. To appro-
priately calculate eGFR, all Scr measurements 
were recalibrated to standardized creatinine 
measurements obtained at the Cleveland Clinic 
Research Laboratory (Cleveland, OH, USA) 
following recommendations of the National 
Kidney Disease Education Program (Myers 
et al. 2006) and NHANES (Selvin et al. 
2007). A recalibration equation was applied 
to Scr in the 2005–2006 survey (standard-
ized creatinine = –0.016 + 0.978 × NHANES 
2005–2006 uncalibrated Scr). No correction 
to the creatinine values in the 2003–2004 sur-
vey was needed (Selvin et al. 2007).
Scr-based eGFR was calculated using 
the modified four-variable Modification of 
Diet in Renal Disease (MDRD) Study equa-
tion (Levey et al. 2006) and the newly devel-
oped Chronic Kidney Disease Epidemiology 
Collaboration (CKD-EPI) equation (Levey 
et al. 2009):
eGFRMDRD (mL/min/m2) =  
175.0 × (Scr)–1.154 × age–0.203  
× 0.742 (if female)  
× 1.212 (if black), 
where age was expressed in years and Scr was 
standardized Scr level in milligrams per deciliter;
eGFRCKD-EPI (mL/min/m2) =  
141 × min(Scr/κ, 1)α  
× max(Scr/κ, 1)–1.029 × 0.993Age  
× 1.018 (if female) × 1.159 (if black),
where Scr is standardized Scr, κ is 0.7 for 
females and 0.9 for males, α is –0.329 for 
females and –0.411 for males, min indicates 
the minimum of Scr/κ or 1, and max indi-
cates the maximum of Scr/κ or 1.
We classified the participants into 
the following three categories: partici-
pants who had normal renal function with 
eGFR ≥ 90 mL/min/m2, participants who 
had mildly decreased renal function with 
eGFR ≥ 60 but < 90 mL/min/m2, and partici-
pants who had chronic kidney disease (CKD) 
with eGFR < 60 mL/min/m2 (National 
Kidney Foundation 2002).
Covariates. Unadjusted urinary concen-
trations of BPA and APs (nanograms per 
milliliter) were used with urinary creatinine 
(milligrams per deciliter) adjusted in the 
model, according to previous recommenda-
tions (Barr et al. 2005). Several factors were 
evaluated for potential confounding and 
included in the statistical models: education 
level [less than high school diploma; high 
school diploma, including General Equivalent 
Diploma (GED); and at least some col-
lege education], annual household income 
(< $25,000, $25,000–55,000, > $55,000, and 
unclear), body mass index (BMI), waist cir-
cumference, dietary intake of energy, cigarette 
smoking status (nonsmoker, former smoker, 
and current smoker), alcohol drinking sta-
tus (nondrinker, former drinker, and current 
drinker), and daily activities (sits/not walk 
very much, walk/not carry much, light load, 
and heavy work by incorporating accelerom-
eter measures). Because both equations for 
eGFR include not only creatinine but also 
Table 1. Baseline demographic and selected risk factors by eGFRMDRD category (n = 2,573).a
eGFRMDRD, mL/min/1.73 m2
Participant characteristic ≥ 90 (n = 1,074) 60–90 (n = 1,231) < 60 (n = 268) p-Valueb
Male 559 (51.6) 648 (51.0) 129 (40.1) 0.0059
Age at screening (years) 38.0 (37.3–38.6) 49.8 (48.6–50.9) 71.4 (69.6–73.1) < 0.0001
Race/ethnicity < 0.0001
Mexican American 270 (12.0) 181 (4.2) 24 (1.5 )
Other Hispanic 45 (5.1) 43 (3.1) 4 (1.3)
Non-Hispanic white 392 (59.4) 775 (81.2) 197 (85.4)
Non-Hispanic black 316 (16.6) 185 (6.7) 31 (5.9)
Other race 51 (6.9) 47 (4.9) 12 (5.9)
Educational attainment < 0.0001
Less than high school diploma 322 (20.4) 278 (12.8) 94 (27.7)
High school diploma (including GED) 259 (26.2) 298 (24.3) 68 (26.8)
Some college or above 493 (53.4) 655 (62.8) 104 (45.5)
Household income < 0.0001
< $25,000 324 (24.4) 336 (18.7) 106 (36.4)
$25,000–55,000 355 (33.4) 368 (29.2) 89 (38.4)
> $55,000 339 (42.2) 458 (52.1) 45 (25.2)
BMI (kg/m2) 27.7 (27.2–28.2) 28.6 (28.2–29.1) 29.2 (28.3–30.2) 0.0004
Waist circumference (cm) 94.9 (93.6–96.1) 98.4 (97.4–99.4) 102.4 (100.0–104.8) < 0.0001
Dietary energy intake (kcal) 2333.2 (2255.9–2410.5) 2150.6 (2075.7–2225.6) 1632.4 (1537.5–1727.2) < 0.0001
Cigarette smoking status < 0.0001
Nonsmoker 549 (48.4) 620 (51.5) 132 (51.2)
Former smoker 161 (15.0) 334 (25.3) 106 (37.9)
Current smoker 363 (36.7) 274 (23.2) 29 (10.9)
Alcohol drinking status < 0.0001
Nondrinker 116 (10.0) 151 (10.2) 56 (23.0)
Former drinker 173 (14.6) 220 (16.1) 85 (28.7)
Current drinker 697 (75.5) 795 (73.7) 106 (48.3)
Daily activities < 0.0001
Sits/not walk very much 217 (20.6) 314 (25.6) 95 (29.0)
Walk/not carry much 567 (51.7) 620 (47.9) 133 (52.7)
Light load 181 (18.0) 226 (20.5) 33 (16.6)
Heavy work 107 (9.8) 71 (6.1) 6 (1.6)
CVDc 6.37 (0.71)d 8.12 (0.98) 16.47 (3.11) < 0.0001
aValues are unweighted frequencies (weighted percentages, %) or weighted means (95% confidence intervals). bRao–Scott chi-square test for categorical data, and survey regression 
model for continuous variables. cCVD includes angina, coronary heart disease, heart attack, and shock. dValue is age-standardized prevalence rate (standard error).Bisphenol A and renal function
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age, sex, and race, further adjustments for 
these three variables may lead to overadjust-
ment. Thus, we present results without adjust-
ing for these variables. However, we have 
conducted analyses by additionally adjust-
ing for age, sex, and race. In the 2003–2006 
NHANES, participants were also asked to 
provide self-reported data on physician diag-
nosis of several diseases and symptoms. In 
our study, cardiovascular disease (CVD) was 
defined as self-reported history of angina, cor-
onary heart disease, heart attack, and shock. 
We calculated age-standardized CVD preva-
lence using the 2000 Census data for the U.S. 
population (U.S. Census Bureau 2007).
Statistical analysis. We performed statisti-
cal analyses using the “Survey” procedure in 
SAS software (version 9.2; SAS Institute Inc., 
Cary, NC, USA) to estimate variance after 
incorporating the weights for the sample popu-
lation, which take into account unequal selec-
tion probabilities and planned oversampling of 
certain subgroups that result from the complex 
multistage probability design in the NHANES.
To investigate the association between 
urinary excretion of BPA and APs, and renal 
function, we used regression models in the 
“Survey” procedure to calculate geometric 
means of urinary BPA and AP concentrations 
by eGFR category, after adjusting for poten-
tial confounding factors. Tests for trends were 
performed by entering the categorical vari-
ables as continuous variables in the model. All 
of the reported p-values were two-tailed, and 
statistical significance was set at 0.05.
Results
Of the 2,573 subjects without known renal 
diseases, 1,074 (41.7%) had normal renal 
function, 1,231 (47.8%) had mildly decreased 
renal function, and 268 (10.4%) had undi-
agnosed CKD when we used the MDRD 
Study equation. The CKD-EPI equation 
led to a higher prevalence of normal renal 
function (57.4%) and a lower prevalence of 
mildly decreased renal function (33.1%). 
Tables 1 and 2 show baseline characteristics 
of participants by eGFR category estimated 
by using the two equations. Overall, par-
ticipants with lower eGFR levels were more 
likely to be older, non-Hispanic white, for-
mer smokers, former alcohol drinkers, and 
physically inactive and to have had a lower 
educational attainment, lower income, a 
higher BMI, a higher waist circumference, 
and a lower dietary energy intake regardless 
of the equation. However, we observed sig-
nificant differences in eGFR by sex only 
when we used the MDRD Study equation, 
and not the CKD-EPI equation. Compared 
with participants having normal renal func-
tion, participants with progressively impaired 
renal function had higher age-standardized 
CVD prevalence when we used the MDRD 
Study equation (6.37%, 8.12%, and 16.47%, 
respectively; p for trend < 0.01) or the CKD-
EPI equation (6.07%, 9.31%, and 20.11%, 
respectively; p for trend < 0.01).
Table 3 presents the associations of renal 
function with urinary BPA and APs. The 
adjusted geometric means for urinary BPA 
excretion decreased with decreasing renal 
function using the MDRD Study equation, 
from 2.46 ng/mL for those with normal renal 
function to 2.31 ng/mL for those with mildly 
decreased renal function, and to 2.04 ng/
mL for those with CKD (p for trend = 0.04). 
Although the trend of BPA excretion with 
eGFR was similar when we used the CKD-
EPI equation, the test for trend was not sta-
tistically significant (p for trend = 0.41). We 
also found that the adjusted geometric means 
for urinary triclosan excretion decreased 
with decreasing levels of eGFR regardless of 
Table 2. Baseline demographic and selected risk factors by eGFRCKD-EPI category (n = 2,573).a
eGFREPI-CKD, mL/min/1.73 m2
Participant characteristic ≥ 90 (n = 1,477) 60–90 (n = 851) < 60 (n = 245) p-Valueb
Male 747 (49.8) 461 (52.7) 128 (44.9) 0.2105
Age at screening (years) 38.9 (38.1–39.7) 55.7 (54.0–57.4) 73.5 (71.7–75.3) < 0.0001
Race/ethnicity < 0.0001
Mexican American 344 (10.2) 111 (2.6) 20 (1.4 )
Other Hispanic 66 (4.8) 22 (2.2) 4 (1.5)
Non-Hispanic white 632 (65.6) 554 (83.5) 178 (84.8)
Non-Hispanic black 364 (12.7) 134 (7.3) 34 (7.4)
Other race 71 (6.6) 30 (4.4) 9 (4.8)
Educational attainment < 0.0001
Less than high school diploma 385 (16.9) 219 (14.4) 90 (30.8)
High school diploma (including GED) 348 (25.3) 213 (24.5) 64 (29.2)
Some college or above 744 (57.8) 419 (61.1) 89 (40.0)
Household income < 0.0001
< $25,000 413 (21.6) 257 (20.9) 96 (36.0)
$25,000–55,000 479 (32.2) 249 (28.5) 84 (41.4)
> $55,000 511 (46.2) 292 (50.5) 39 (22.6)
BMI (kg/m2) 27.9 (27.5–28.4) 28.8 (28.4–29.2) 29.2 (28.3–30.1) 0.0031
Waist circumference (cm) 95.3 (94.2–96.5) 99.7 (98.7–100.8) 103.3 (101.1–105.5) < 0.0001
Dietary energy intake (kcal) 2293.0 (2221.4–2364.6) 2091.4 (2017.9–2164.9) 1644.3 (1522.7–1765.8) < 0.0001
Cigarette smoking status < 0.0001
Nonsmoker 768 (50.1) 409 (50.2) 124 (52.4)
Former smoker 215 (15.2) 290 (31.7) 96 (37.0)
Current smoker 492 (34.7) 150 (18.1) 24 (10.6)
Alcohol drinking status < 0.0001
Nondrinker 160 (9.7) 110 (11.1) 53 (23.8)
Former drinker 218 (13.4) 184 (19.5) 76 (29.5)
Current drinker 994 (76.9) 508 (69.5) 96 (46.6)
Daily activities < 0.0001
Sits/not walk very much 301 (21.0) 231 (27.3) 94 (33.1)
Walk/not carry much 762 (50.3) 438 (48.0) 120 (53.8)
Light load 270 (19.5) 145 (19.9) 25 (12.2)
Heavy work 142 (9.1) 37 (4.9) 5 (0.9)
CVDc 6.07 (0.73)d 9.31 (1.44) 20.11 (3.25) < 0.0001
aValues are unweighted frequency (weighted percentages, %) or weighted means (95% confidence intervals). bRao–Scott chi-square test for categorical data, and survey regression 
model for continuous variables. cCVD includes angina, coronary heart disease, heart attack, and shock. dValue is age-standardized prevalence rate (standard error).You et al.
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the equation (p for trend < 0.01 and 0.01, 
respectively, for MDRD Study and CKD-
EPI equations). However, we did not find 
an association between urinary BP-3 and 
renal function (p for trend = 0.30 and 0.64, 
respectively). We also conducted analyses by 
including age, sex, and race in the models and 
found that the associations did not change 
substantially (data not shown).
To examine whether sex and age mod-
ify the association between renal function 
and excretion of environmental phenols, we 
conducted stratified analyses by sex (male, 
female) and age (≥ 65 years, < 65 years). 
The association between BPA excretion and 
renal function appeared primarily in females 
(p for trend = 0.03), and not in males (p for 
trend = 0.97), when we used the MDRD 
Study equation (Table 4). The test for interac-
tion was not significant. When we used the 
CKD-EPI equation, the adjusted geometric 
means for urinary BPA excretion still decreased 
with decreasing renal function among females, 
from 1.90 ng/mL for those with normal renal 
function to 1.81 ng/mL for those with mildly 
decreased renal function, to 1.57 ng/mL 
for those with CKD, but the trend was not 
statistically significant (p for trend = 0.29). 
The average excretion for urinary triclosan 
decreased with reducing levels of eGFR among 
both males and females regardless of the equa-
tion, although the p-value for interaction was 
not statistically significant. We found no asso-
ciation between urinary BP-3 and renal func-
tion in males or females, although the BP-3 
concentrations for females were significantly 
higher than those for males in each eGFR cat-
egory. Urinary excretion of triclosan decreased 
with reducing renal function among younger 
participants (p for trend < 0.01 and 0.02, 
respectively, for MDRD Study and CKD-EPI 
equations) but not among older participants. 
The interactions between triclosan and age 
were statistically significant (p-value = 0.02 
and 0.04, respectively, for MDRD Study and 
CKD-EPI equations).
Discussion
In the present study, we found that persons 
without known renal diseases (n = 1,499 
using the MDRD Study equation, and 
n = 1,096 using the CKD-EPI equation) had 
mildly decreased renal function or undiag-
nosed CKD. Urinary excretion levels of BPA 
significantly decreased with decreasing renal 
function when we used the MDRD Study 
equation, but the association was not signifi-
cant when we used the CKD-EPI equation. 
Urinary excretion levels of triclosan decreased 
with decreasing renal function regardless of 
the equation. Conversely, we did not find a 
similar association for BP-3. For BPA, the 
association appeared primarily in females. For 
triclosan, the association appeared in both 
males and females. Furthermore, the associa-
tion for triclosan primarily appeared among 
those < 65 years of age. To our knowledge, 
this is the first study to examine the associa-
tions between renal function and excretion 
levels of urinary environmental phenols.
Table 3. Adjusted geometric mean concentrations and 95% confidence intervals of the environmental phenols BPA and APs (ng/mL) by level of eGFR.
Environmental 
phenol
eGFRMDRD, mL/min/1.73 m2 eGFRCKD-EPI, mL/min/1.73 m2
≥ 90 60–90 < 60
p-Value 
for trenda ≥ 90 60–90 < 60
p-Value 
for trenda
BPA 2.46 (2.41–0.2.50) 2.31 (2.31–2.31) 2.04 (1.76–2.36) 0.04 2.37 (2.37–2.37) 2.31 (2.09–2.56) 2.22 (1.92–2.56) 0.41
BP-3 11.86 (11.86–11.86) 13.92 (13.92–13.92) 11.89 (8.43–16.77) 0.30 12.48 (12.48–12.48) 14.15 (14.15–14.15) 10.15 (6.64–15.53) 0.64
Triclosan 19.40 (13.66–27.56) 14.68 (11.17–19.29) 13.76 (8.62–21.98) 0.003 18.75 (13.36–26.31) 14.21 (10.04–20.12) 13.56 (8.21–22.41) 0.01
aSurvey regression models were used after adjusting for educational attainment, household income, number of people in the household, BMI, waist circumference, smoking status, 
alcohol drinking, dietary energy intake, daily activities, CVD, and urinary creatinine.
Table 4. Adjusted geometric mean concentration and 95% confidence intervals of the environmental phenols BPA and APs by level of eGFR, stratified by sex or age.
eGFRMDRD, mL/min/1.73 m2 eGFRCKD-EPI, mL/min/1.73 m2
Environmental 
phenol ≥ 90 60–90 < 60
p-Value 
for trenda
p-Value for 
interaction ≥ 90 60–90 < 60
p-Value 
for trenda
p-Value for 
interaction
BPA
Male 2.65 
(2.65–2.65)
2.70 
(2.70–2.70)
2.49 
(2.00–3.10)
0.97 0.19 2.89 
(2.40–3.47)
2.95 
(2.32–3.76)
3.25 
(2.27–4.65)
0.75 0.55
Female 2.06 
(1.52–2.79)
1.77 
(1.31–2.39)
1.52 
(1.14–2.02)
0.03 1.90 
(1.42–2.55)
1.81 
(1.31–2.49)
1.57 
(1.18–2.10)
0.29
≥ 65 years 2.62 
(1.45–4.72)
2.04 
(1.42–2.93)
2.04 
(1.40–2.97)
0.30 0.75 2.30 
(1.34–3.94)
2.00 
(1.38–2.90)
2.07 
(1.43–3.00)
0.74 0.73
< 65 years 2.65 
(2.35–2.99)
2.55 
(2.32–2.79)
1.88 
(1.16–3.04)
0.18 2.58 
(2.40–2.77)
2.58 
(2.17–3.07)
2.38 
(1.38–4.09)
0.94
BP-3
Male 8.18 
(8.18–8.18)
10.06 
(10.06–10.06)
7.14 
(4.99–10.21)
0.32 0.61 9.91 
(6.39–15.37)
12.83 
(7.47–22.01)
7.34 
(3.35–16.07)
0.72 0.99
Female 25.10 
(17.16–36.74)
27.13 
(17.52–42.03)
20.76 
(10.20–42.24)
0.94 25.24 
(17.37–36.68)
26.22 
(16.21–42.39)
19.90 
(8.97–44.18)
0.80
≥ 65 years 9.59 
(3.26–28.19)
8.03 
(3.48–18.51)
7.40 
(2.73–20.11)
0.64 0.01 10.38 
(5.19–20.76)
7.99 
(3.22–19.80)
6.48 
(2.39–17.59)
0.31 0.004
< 65 years 13.61 
(12.31–15.05)
17.05 
(14.52–20.01)
18.67 
(12.09–28.83)
0.06 14.12 
(12.84–15.53)
17.71 
(17.71–17.71)
15.75 
(6.41–38.71)
0.09
Triclosan
Male 23.05 
(14.44–36.79)
17.85 
(12.21–26.09)
14.42 
(7.69–27.03)
0.07 0.89 23.84 
(11.12–51.11)
21.25 
(8.38–53.87)
14.51 
(5.48–38.40)
0.14 0.66
Female 18.84 
(9.01–39.98)
13.53 
(6.91–26.49)
14.87 
(6.91–32.02)
0.07 18.82 
(9.18–38.59)
11.58 
(5.94–22.55)
16.52 
(6.52–41.87)
0.03
≥ 65 years 9.92 
(4.30–22.88)
5.74 
(3.19–10.34)
7.41 
(3.51–15.66)
0.91 0.02 12.17 
(5.78–25.60)
5.42 
(2.83–10.40)
6.23 
(3.05–12.72)
0.19 0.04
< 65 years 21.74 
(13.99–33.78)
16.80  
(11.69–24.16)
8.45  
(3.97–17.99)
0.008 20.88  
(13.66–31.91)
15.98 
(9.99–25.57)
7.98  
(3.92–16.25)
0.02
aSurvey regression models were used after adjusting for educational attainment, household income, number of people in the household, BMI, waist circumference, smoking status, 
alcohol drinking, dietary energy intake, daily activities, CVD, and urinary creatinine.Bisphenol A and renal function
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Humans are exposed to a vast number of 
man-made chemicals, and the consequences of 
these exposures have not been clearly defined 
and are sometimes controversial (Turner and 
Sharpe 1997; Vandenberg et al. 2009). BPA 
and APs, particularly BPA, have been placed 
at the center of debate because of their phe-
nol structure and hormone-like effects on the 
endocrine system and their adverse effects on 
human health (Amaral Mendes 2002). In the 
last decade, several epidemiological studies 
have investigated the relationship between 
BPA exposure and health-related end points, 
such as circulating sex hormone abnormi-
ties (Hanaoka et al. 2002), polycystic ovary 
syndrome (Takeuchi and Tsutsumi 2002; 
Takeuchi et al. 2004), fetuses with abnor-
mal karyotype (Yamada et al. 2002), sterility 
(Kuroda et al. 2003), endometrial carcinoma 
and hyperplasia (Hiroi et al. 2004), obesity 
(Takeuchi et al. 2004), recurrent miscarriage 
(Sugiura-Ogasawara et al. 2005), and more 
recently, CVD, diabetes, and abnormal con-
centrations of liver enzymes (Lang et al. 2008; 
Melzer et al. 2010). In humans, it is gener-
ally understood that most ingested environ-
mental phenols are rapidly conjugated with 
glucuronic acid in the gut wall and liver and 
almost completely excreted in urine as highly 
water-soluble metabolites with short terminal 
half-lives (Dekant and Völkel 2008; Ye et al. 
2005). Because of sample abundance and 
noninvasiveness of urine collection compared 
with blood samples (Needham and Sexton 
2000), most previous human studies have 
used total concentrations of BPA, tOP, BP-3, 
and triclosan in urine as biomarkers to assess 
exposure risk (Calafat et al. 2008a, 2008b, 
2008c; Lang et al. 2008; Melzer et al. 2010; 
Ye et al. 2005). The kidneys are the major 
organs for the excretion of these environmen-
tal phenols. Renal excretion of xenobiotics 
is dependent on glomerular filtration rate, 
renal tubular secretion, and reabsorption. 
Some organic compounds, such as phenols, 
are glucuronidated in the liver and eliminated 
by active tubular secretion (Boeniger et al. 
1993). In our study, we found that impaired 
renal function was associated with reduced 
excretion of triclosan, and perhaps BPA. The 
exact mechanism for the reduced excretion of 
some environmental phenols in CKD patients 
is not clear. Although accumulation of these 
environmental phenols is one possible expla-
nation, it is also possible that these environ-
mental phenols are metabolized elsewhere or 
circulated in an inactive form, such as conju-
gated phenols (Kanno et al. 2007; Murakami 
et al. 2007; Swan and Bennett 1992; Tett 
et al. 2003; Turnheim 1991).
CKD is a common and an increasing 
health threat among adults in the United 
States and worldwide (Coresh et al. 2007; 
Meguid El Nahas and Bello 2005). Recent 
U.S. CKD prevalence estimates indicate that 
15.3% of the civilian noninstitutionalized 
population has CKD (Whaley-Connell et al. 
2008). Compared with its high prevalence, 
the disease awareness among U.S. adults is 
generally low (Plantinga et al. 2008). It is 
well documented that patients with CKD 
have a high risk for premature death as a 
result of CVD compared with the general 
population (Foley et al. 1998). The mecha-
nisms underlying this increased risk of CVD 
among CKD patients are not entirely clear 
(Stenvinkel et al. 2008). Two recent reports 
found a link between urinary BPA concentra-
tions and prevalence of heart diseases using 
2003–2006 NHANES data, suggesting 
an association between BPA exposure and 
CVD (Lang et al. 2008; Melzer et al. 2010). 
Previous studies suggest that conjugated 
BPA may be deconjugated into biologically 
active forms in some situations (Vandenberg 
et al. 2009). Future studies are necessary to 
investigate this issue among CKD patients or 
those with mildly decreased renal function. 
Importantly, in patients with end-stage renal 
disease on hemodialysis, in addition to almost 
complete loss of renal function and therefore 
loss of the ability to excrete environmental 
phenols, hemodializers may be an extra source 
for BPA accumulation in the body (Haishima 
et al. 2001; Yamasaki et al. 2001). Therefore, 
further studies are warranted to evaluate the 
associations between environmental phenols 
in the body and risk of CVD among those 
with CKD patients.
Based on Scr level, age, sex, and race, the 
MDRD Study equation is recommended 
in the National Kidney Foundation Kidney 
Disease Outcomes Quality Initiative classifi-
cation guidelines and is the most widely used 
equation in the clinic, as well as epidemio-
logical studies (Coresh et al. 2007; Levey et al. 
2007). Its limitations include imprecision and 
systematic underestimation of measured glom-
erular filtration rate at higher values (Stevens 
et al. 2007). The newly developed CKD-EPI 
equation has been shown to overcome these 
limitations to some extent (Levey et al. 2009). 
In the present study, we conducted analyses 
using both equations. The CKD-EPI equa-
tion yielded a higher prevalence of normal 
renal function (57.4% vs. 41.7%) and a lower 
prevalence of mildly decreased renal function 
(33.1% vs. 47.8%) compared with rates gen-
erated with the MDRD Study equation. This 
finding is consistent with results from a recent 
report (Stevens et al. 2010). Furthermore, the 
significant difference in eGFR by sex and the 
significant association between urinary BPA 
and eGFR found using the MDRD Study 
equation became nonsignificant when we 
used the CKD-EPI equation. We cannot give 
an exact explanation for the different results 
from two equations because no measured 
glomerular filtration rate was available in the 
study. Therefore, future studies are needed to 
further investigate the association of urinary 
as well as blood BPA and other phenols with 
kidney function using measured glomerular 
filtration rate.
One interesting trend in the present study 
is that the differences in urinary BPA excre-
tions between males and females increased 
with reduced eGFR categories regardless of 
the equation used. We observed reduced 
urinary levels of BPA with decreasing renal 
function only in females, and not in males, 
although this was significant only when we 
used the MDRD Study equation. The under-
lying mechanisms for the findings are unclear. 
Sex-associated pharmacokinetic and phar-
macodynamic differences in phenol metabo-
lism may explain at least part of these results 
(Schwartz 2003). Particularly, given that BPA 
has a structure similar to that of estrogens, it is 
conceivable that metabolism patterns could be 
different in males and females because of the 
different levels of enzymes related to estrogens 
and estrogen metabolism. On the other hand, 
the different associations by sex could be due 
to chance because we did not find a statisti-
cally significant interaction. These findings 
need to be replicated in future studies with 
larger sample sizes.
We observed no differences in urinary 
excretion of BP-3 by eGFR category. BP-3, 
also known as oxybenzone, is a monomethox-
ylated and monohydroxylated derivative of 
benzophenone. BP-3 is a principal compo-
nent of ultraviolet filters as well as an indirect 
food additive (Gonzalez et al. 2006). The dif-
ferent results of BP-3 from BPA and triclosan 
in our study can probably be explained by its 
different chemical structure and physical and 
chemical properties.
This study has several strengths and impli-
cations. This is a population-based study with 
nationally representative samples. Participation 
rates for the interview and medical examina-
tion center during 2003–2006 NHANES 
were high, which may minimize potential 
selection biases. We excluded from analyses 
participants with self-reported kidney disease 
to minimize the influence of diet change on 
exposure. However, as with all prevalent case–
control studies, one major concern is that the 
temporal sequence may not be clear. It is pos-
sible that the associations of urinary excre-
tions of BPA and triclosan with renal function 
may be solely due to lower dietary intakes, 
and thus a lower exposure, among those with 
poorer renal function. However, we have 
adjusted for total energy intake and BMI as 
well as potential confounding factors in the 
model. Also, we did not find a similar associa-
tion for urinary BP-3. Furthermore, we found 
a positive association between urinary BPA 
and renal function among females, but not You et al.
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among males, indicating that the association 
cannot be explained entirely by differences in 
dietary intake. In the present study, we used 
eGFR estimated by the MDRD Study equa-
tion and the CKD-EPI equation and found 
some different results, particularly for BPA. 
In the present study, we used eGFR estimated 
by the MDRD Study equation and the CKD-
EPI equation and found different results, par-
ticularly for BPA. In addition, in our study we 
used the estimated eGFR as a measure of renal 
function, which is based on Scr. Therefore, 
future studies should use measured glomeru-
lar filtration rate. Because we used spot urine 
samples to estimate concentrations of BPA and 
APs, urine creatinine needs to be used to cor-
rect for urine dilution. However, the adjusted 
geometric means for urinary creatinine excre-
tion significantly increased with decreasing 
renal function (p for trend < 0.01), from 91.71 
mg/dL for those with normal renal function to 
112.68 mg/dL for those with mildly decreased 
renal function, to 145.62 mg/dL for those 
with CKD using the MDRD Study equation, 
and we found the same significant trend when 
we used CKD-EPI equation with the corre-
sponding geometric means of 94.29, 113.77, 
and 146.67 mg/dL, respectively (p for trend 
< 0.01). In other words, it is possible that even 
though BPA and APs are not actually associ-
ated with renal function, we may still find a 
correlation due to the association between Scr 
and urinary creatinine. Thus, we used uncor-
rected BPA and APs as dependent variables 
and included urinary creatinine as a covariate 
in regression models as recommended previ-
ously (Lang et al. 2008; Melzer et al. 2010). 
However, it is still possible that adjusting for 
urinary creatinine as a covariate may lead to 
potential bias, although the nature of bias is 
hard to predict, particularly if a larger propor-
tion of creatinine in the urine of individuals 
with renal dysfunction is present because of 
pathways independent of glomerular filtra-
tion. In this regard, further studies measuring 
concentrations of BPA and APs in 24-hour 
urine samples are warranted to address this 
issue. Given the widespread human exposure 
to environmental phenols, future human stud-
ies of BPA and other environmental phenols 
should measure serum levels of these com-
pounds in addition to urinary excretion levels. 
It is very important to understand the mecha-
nisms by which the kidneys excrete environ-
mental phenols, particularly in animal models 
of impaired renal function.
Conclusion
Urinary excretion levels of triclosan, and possi-
bly BPA, decreased with decreasing renal func-
tion. The associations might differ by age and/
or sex. Further studies, particularly prospective 
studies with measurements from both serum 
levels and urinary excretions of environmental 
phenols, are warranted to evaluate the con-
tribution of environmental phenols to the 
development of complications, including car-
diovascular complication in CKD population.
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